RxDoctor Payments Data

Margreth Brontoli, MD

Ophthalmology · Long Beach, NYNPI 1235142639

Payments from drug & device makers

$988in general payments, 2019–2025

Across 30 payments — averaging $32.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$281
  • Sun Pharmaceutical Industries Inc.$202
  • Bausch & Lomb Americas Inc.$123
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$92
  • AbbVie$65
  • Kala Pharmaceuticals, Inc.$56
  • plus $169 from 6 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 45th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$111,657
Medicare patients
398
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine55$45,188
LumiganBimatoprost33$14,678
MieboPerfluorohexyloctane/Pf14$10,625
Alphagan PBrimonidine Tartrate35$10,342
CombiganBrimonidine Tartrate/Timolol16$3,637
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha159$1,754
Timolol Maleate41$962
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$199
Latanoprost36$169
ErythromycinErythromycin Base12$149
Doxycycline Hyclate20$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$65$73,845139 claims
Bausch & Lomb Americas Inc.Miebo$123$10,62514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Long Beach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →